Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Bedrock Healthcare

- PMLiVE

Lilly to acquire LimmaTech Biologics and Vaccine Company in deals totalling $2.33bn

The acquisitions reinforce the company’s commitment to reduce the long-term burden of serious disease

- PMLiVE

Lilly to acquire Curevo in deal worth $1.5bn

The acquisition will help build Lilly’s infectious disease portfolio

- PMLiVE

Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1bn

Catalyst Pharmaceuticals is focused on novel medicines for rare diseases

Two_Women_Running_Making_Health_Whole

The silent drop-off: How disengagement shows up in everyday behaviour

In healthcare, disengagement rarely announces itself. It doesn’t always appear as refusal or a clear decision to stop treatment. More often, it shows up quietly, in what is delayed, avoided...

Mednet

- PMLiVE

Eli Lilly to acquire Kelonia Therapeutics in deal worth up to $7bn

The acquisition will help Lilly to expand its capabilities in cell and gene therapy

- PMLiVE

Lilly to acquire Centessa in deal worth up to $7.8bn

The companies aim to advance treatments for narcolepsy and other sleep-wake disorders

- PMLiVE

Biogen to acquire Apellis in $5.6bn deal

The deal will enhance Biogen’s growth portfolio in immunology and rare disease

- PMLiVE

Gilead to acquire Tubulis for up to $5bn

The acquisition builds on Gilead’s oncology pipeline, focused on addressing areas of high unmet need

- PMLiVE

Novartis to acquire Excellergy in deal worth up to $2bn

Exl-111, a potential treatment included in the deal, is a central factor in many allergic diseases

Grace Communications logo

GRACE COMMS acquisition of WORDBIRD creates a merger of two independent, strategic and creative healthcare agencies

We are delighted to announce that Grace Comms and Wordbird Limited, both healthcare brand comms agencies with a creative mission in healthcare and a passion for people, are coming together....

Grace Communications

- PMLiVE

Novartis agrees on potential $3bn deal to buy Synnovations’s breast cancer treatment

The oral drug is currently being evaluated for breast cancer and other advanced solid tumours in a phase 1/2 study

Printed version of 'The participation equation'

Behind the scenes: why we created ‘The participation equation’

Go behind the scenes of The participation equation – our call to put people, not just data, at the heart of clinical research.

Cuttsy + Cuttsy

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links